Anthem Biosciences Limited
Manulife Investment Management bought 1,95,802 shares of Anthem Biosciences Limited for ₹14.58 Cr at ₹744.80 apiece in a block deal.
A biotechnology company providing contract research, development, and manufacturing services alongside specialty ingredients production. Established in 2006, the company serves pharmaceutical and nutraceutical sectors through its integrated CRDMO capabilities and custom synthesis expertise. Its distinctive position lies in combining comprehensive development expertise with in-house manufacturing facilities, enabling end-to-end solutions for clients requiring specialized ingredient formulation, process optimization, and commercial-scale production services.
Manulife Investment Management's active India and Pacific Asia equity vehicles. Its India Equity strategy launched in 2012 and uses bottom-up fundamental research to find companies with durable competitive advantages, identifiable catalysts and growth not fully reflected in valuations. Manulife manages US$570.2 billion globally, including US$873.59 million in its India Equity strategy.